RxDoctor Payments Data

Alison Richardson, MD

Family Medicine · Little Rock, ARNPI 1457318065

Payments from drug & device makers

$5,970in general payments, 2019–2025

Across 303 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$750
  • Novo Nordisk$692
  • AbbVie$684
  • Takeda Pharmaceuticals U.S.A., Inc.$455
  • Pfizer$401
  • Abbott$348
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$5,91399%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,970 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$153,466
Medicare patients
464
Services billed
3,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$96,248
FarxigaDapagliflozin Propanediol28$26,981
RybelsusSemaglutide19$25,567
JanuviaSitagliptin Phosphate24$20,074
EliquisApixaban20$19,478
LinzessLinaclotide15$16,066
TrulicityDulaglutide14$13,476
Tresiba Flextouch U-200Insulin Degludec11$10,085
MyrbetriqMirabegron16$8,212
SymbicortBudesonide/Formoterol Fumarate23$6,544
Varenicline Tartrate11$2,567
Levothyroxine Sodium311$2,406
Atorvastatin Calcium262$2,017
SynthroidLevothyroxine Sodium39$1,981
Losartan Potassium205$1,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$692$121,814102 claims
AstraZenecaFarxiga, Symbicort$750$33,52451 claims
MerckJanuvia$138$20,07424 claims
PfizerEliquis$401$19,47820 claims
AbbVieLinzess, Synthroid$684$18,04654 claims
Lilly USA, LLCTrulicity$295$13,47614 claims
Astellas Pharma US IncMyrbetriq$39$8,21216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →